{"entity": "researcher", "timestamp": "2026-09-30T03:00:51.934Z", "family": "Cristiano", "given": "Antonio", "initials": "A", "orcid": "0000-0001-7055-8577", "affiliations": ["Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/08d1e34f9ae54428a57efb64d8347de4.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/08d1e34f9ae54428a57efb64d8347de4"}}, "publications": [{"entity": "publication", "iuid": "3c4322420aae46e09e712f1286cbb8d8", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/3c4322420aae46e09e712f1286cbb8d8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/3c4322420aae46e09e712f1286cbb8d8"}}, "title": "Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.", "authors": [{"family": "Voso", "given": "Maria-Teresa", "initials": "MT", "orcid": "0000-0002-6164-4761", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3a6ddb1ad1db4db38ef8bd982bd607af.json"}}, {"family": "Pandzic", "given": "Tatjana", "initials": "T"}, {"family": "Falconi", "given": "Giulia", "initials": "G", "orcid": "0000-0001-7699-1427", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7229a2587e5a4a4cb6e2e17f018dc19b.json"}}, {"family": "Den\u010di\u0107-Fekete", "given": "Marija", "initials": "M"}, {"family": "De Bellis", "given": "Eleonora", "initials": "E"}, {"family": "Scarfo", "given": "Lydia", "initials": "L"}, {"family": "Ljungstr\u00f6m", "given": "Viktor", "initials": "V"}, {"family": "Iskas", "given": "Michail", "initials": "M"}, {"family": "Del Poeta", "given": "Giovanni", "initials": "G"}, {"family": "Ranghetti", "given": "Pamela", "initials": "P"}, {"family": "Laidou", "given": "Stamatia", "initials": "S"}, {"family": "Cristiano", "given": "Antonio", "initials": "A", "orcid": "0000-0001-7055-8577", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/08d1e34f9ae54428a57efb64d8347de4.json"}}, {"family": "Plevova", "given": "Karla", "initials": "K"}, {"family": "Imbergamo", "given": "Silvia", "initials": "S"}, {"family": "Engvall", "given": "Marie", "initials": "M"}, {"family": "Zucchetto", "given": "Antonella", "initials": "A"}, {"family": "Salvetti", "given": "Chiara", "initials": "C"}, {"family": "Mauro", "given": "Francesca R", "initials": "FR", "orcid": "0000-0003-2425-9474", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/588b17f8a7544766bdfcd763978dad5d.json"}}, {"family": "Stavroyianni", "given": "Niki", "initials": "N"}, {"family": "Cavelier", "given": "Lucia", "initials": "L"}, {"family": "Ghia", "given": "Paolo", "initials": "P"}, {"family": "Stamatopoulos", "given": "Kostas", "initials": "K"}, {"family": "Fabiani", "given": "Emiliano", "initials": "E", "orcid": "0000-0002-6209-8934", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0f66719fdc5c4349a1123ca096ef57b8.json"}}, {"family": "Baliakas", "given": "Panagiotis", "initials": "P", "orcid": "0000-0002-5634-7156", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2a31997db1ee4ef1aaff75e423b8ccfb.json"}}], "type": "journal article", "published": "2022-07-00", "journal": {"title": "Br. J. Haematol.", "issn": "1365-2141", "volume": "198", "issue": "1", "pages": "103-113", "issn-l": "0007-1048"}, "abstract": "Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia (CLL) who developed a t-MN after treatment with chemo-(immuno)therapy. Using NGS, we detected a total of 30 pathogenic/likely pathogenic (P/LP) variants in 10 of 13 patients with a t-MN (77%, median number of variants for patient: 2, range 0-6). The prevalence of CHIP was then backtracked in paired samples taken at CLL diagnosis in eight of these patients. Six of them carried at least one CHIP-variant at the time of t-MN (median: 2, range: 1-5), and the same variants were present in the CLL sample in five cases. CHIP variants were present in 34 of 285 patients from a population-based CLL cohort, which translates into a significantly higher prevalence of CHIP in patients with a CLL who developed a t-MN, compared to the population-based cohort (5/8, 62.5% vs. 34/285, 12%, p = 0.0001). Our data show that CHIP may be considered as a novel parameter affecting treatment algorithms in patients with CLL, and highlight the potential of using chemo-free therapies in CHIP-positive cases.", "doi": "10.1111/bjh.18129", "pmid": "35277855", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T10:58:22.532Z", "modified": "2026-09-23T10:58:22.815Z"}]}